We investigated the effectiveness of mammalian target of rapamycin (mTOR) inhibitors in canine lung cancer upon PI3K/AKT/mTOR activation in three canine PC cell lines and three mTOR inhibitors (AZD8055, temsirolimus, and everolimus) in vitro and in vivo. The gene discussed is MTOR; the disease is pachyonychia congenita.